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A 57-year-old man with a history of HIV disease, hyperlipidemia, and major depressive
disorder presented to his primary care physician with depression and insomnia. His mood
had been controlled with bupropion, 300 mg/d, for the past several years; however, the
recent death of his husband led to increased hopelessness, insomnia, and decreased
energy. Results of laboratory studies (thyroid-stimulating hormone, complete blood cell
count, and metabolic profile) were unremarkable. His total score on the Patient Health
Questionnaire 9 (PHQ-9) was 16 (Table 1).
Answer
C.Thepatienthasdepressivesymptomsofat leastmoderateseverity.
Test Characteristics
Depression is present in approximately 14% of patients in primary
care settingsbut isoftennotdiagnosed.Whenstandardizedscreen-
ing instruments are not used, general practitioners correctly iden-
tify depression in approximately 47%of patientswith depression.1
The PHQ-9 is a self-report form based on symptoms experienced
over thepast 2weeks that consistsof9 items (0 = not at all, 1 = sev-
eral days, 2 = more than half the days, 3 = nearly every day), which
are summed to yield a score ranging from 0 through 27. Scores of
5-9 represent mild depressive symptoms; 10-14, moderate; 15-19,
moderately severe; and20ormore, severedepressive symptoms.2
A 3- to 5-point change in PHQ-9 score is clinically meaningful.2
In primary care settings, a total score of 10 or higher has an es-
timated sensitivity of 81.3% (95% CI, 71.6%-89.3%), specificity of
85.3% (95% CI, 81.0%-89.1%), positive predictive value (PPV) of
44.2% (95% CI, 41.9%-46.6%), and positive likelihood ratio (LR+)
of 6.9 (95% CI, 6.4-7.4) for major depressive disorder (MDD).3
A higher threshold score (PHQ-9 score 14) has a lower sensitivity
(56.0%)buthigherspecificity (96.6%),PPV(73.4%),andLR+(16.5).3
Advantages of the publicly accessible PHQ-9 include its self-report
format, rapid scoring and interpretation, availability in multiple
languages, suitability for remoteadministration (eg, via telehealth),
and sensitivity to treatment-associated change.2
Application of Test Results to This Patient
Thispatient’sPHQ-9score indicatesdepressivesymptomsofat least
moderateseverity.Hissymptoms,previously in remission,were likely
exacerbated by the recent death of his husband. In addition, his his-
torysupports(butdoesnotconfirm)adiagnosisofMDD;patientswith
dysthymicdisorderor subthresholddepressionwould typicallyhave
PHQ-9 scores lower than 16. Because thePHQ-9doesnot screen for
bipolar disorder, elevated PHQ-9 scores should prompt additional
questionstoexcludebipolardepression, includingaskingaboutasus-
tained period of grandiosity, decreased need for sleep, or pressured
speech. Importantly, the patient was screened for and denied sui-
cidal ideation (item9, Table 1). For patients with a positive response
for item9, the P4 screener asks 4 questions (regarding suicidal past
history, plan, probability, and preventive factors) that stratify pa-
tients into “minimal,” “lower,” and “higher” suicide risk levels.4
Because anxiety co-exists in 30% to 50% of depressed pa-
tients, screening for anxiety with a measure such as the general-
ized anxiety disorder 7-item (GAD-7) scale is also reasonable.2 Ad-
ditionally, inquiry about alcohol and other substance use disorders
iswarranted.Whenscreening fordepression inpatientswithphysi-
cal illness, concern has been raised about whether the 4 somati-
HOW WOULD YOU INTERPRET THESE
TEST RESULTS?
A. The patient has major depressive
disorder.
B. The patient has dysthymic disorder.
C. The patient has depressive
symptoms of at least moderate
severity.
D. The patient does not have bipolar
disorder.
Table 1. Patient’s PHQ-9 Responses at Baseline
Over the Last 2 Weeks, How Often Have You Been Bothered
by Any of the Following Problems?
Not at
All
Several
Days
More
Than
Half the
Days
Nearly
Every
Day
Score per affirmative answer 0 1 2 3
1. Little interest or pleasure in doing things X
2. Feeling down, depressed, or hopeless X
3. Trouble falling or staying asleep, or sleeping too much X
4. Feeling tired or having little energy X
5. Poor appetite or overeating X
6. Feeling bad about yourself or that you are a failure
or have let yourself or your family down
X
7. Trouble concentrating on things, such as reading the
newspaper or watching television
X
8. Moving or speaking so slowly that other people could
have noticed? Or the opposite—being so fidgety or restless
that you have been moving around a lot more than usual
X
9. Thoughts that you would be better off dead
or of hurting yourself in some way
X
Total score = 16 1 6 9
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cally focused items (fatigue,weight/appetite changes, sleepdistur-
bance, andpsychomotor symptoms) are specific toMDD.However,
a study of 235 patients with diabetes or cardiopulmonary disease
and 204without these conditions found that only fatigue was sig-
nificantlymore common inpatientswithphysical illness and that all
4 somatic symptoms showed similar improvement with depres-
sion treatment in patients with and without comorbidity.5
What Are Alternative Diagnostic Testing Approaches?
Manyguidelines, including thoseof theUSPreventiveServicesTask
Force,6 recommend routine screening for depression among adults
andreferencethePHQ-9asoneof thepreferred instruments.TheUS
PreventiveServicesTaskForcealsorecommendstheGeriatricDepres-
sionScale,EdinburghPostnatalDepressionScale, andHospitalAnxi-
ety andDepression Scale,which are specific to definedpopulations
ofpatients(Table2).ThePHQ-9isalsovalidatedfordepressionscreen-
ing inolderadults.9Multipledepressionscalesexist, andaconversion
toolhasbeendevelopedtocross-calibratescoresbetweenthePHQ-9
andotherscales.10 Insteadofusingascreeningtool, cliniciansmay in-
terviewpatients forDSM-5 symptomsofMDDduringhistory-taking.
However, this unstructured assessment typically requires more
time,andthe9symptomsofMDDaremeasuredbythePHQ-9 items.
APHQ-9scoreof 10orhigher shouldpromptamore thoroughevalu-
ation,which is required to establish a diagnosis ofMDD.10
Patient Outcome
The patient was referred to a psychiatrist. Bupropion was in-
creased to 450mg/d and his symptoms improved. Approximately
a year later, his PHQ-9 score had decreased to 4.
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Clinical Bottom Line
• Depression is common in primary care settings.
• The PHQ-9 is a short, publicly available, self-report form that
screens for and tracks clinically significant depressive symptoms.
• Patients with a PHQ-9 score of 10 or higher should be evaluated
for clinical depression and comorbid psychiatric conditions by
either a primary care or mental health clinician (eg, psychologist
or psychiatrist) before initiating treatment.
• The presence of suicidal ideation (item 9) should prompt
a thorough self-harm assessment; several follow-up questions
are suggested (eg, the P4 suicidality screener).
Table 2. Measures Recommended by the US Preventive Services Task Force for Depression Screening
Measure
No. of
Items Target Population
Score
Range
Common Threshold
for Clinically Significant
Depression
Operating Characteristics
for Major Depressive Disorder
ReferenceSensitivity, % Specificity, %
PHQ-9 9 General adult
and adolescent population
0-27 ≥10 82 85 Mitchell et al,3 2016
20 studies (n = 11257)
HADS 7 General
adult population
0-21 ≥8 82 74 Brennan et al,7 2010
11 studies (n = 1735)
GDS-15 15 Elderly (≥65 y) 0-15 ≥6 or 7 81 75 Wancata et al,8 2006
20 studies (n = 2918)
EPDS 7 Women who are pregnant
or 6-8 weeks postpartum
0-30 ≥13 80 90 Siu et al,6 2016
23 studies (n = 5398)
Abbreviations: EPDS, Edinburgh Postnatal Depression Scale; GDS-15, Geriatric Depression Scale (short form); HADS, Hospital Anxiety and Depression Scales;
PHQ-9, Patient Health Questionnaire 9-Item Depression Scale.
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